Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference42 articles.
1. Kasim NA, Whitehouse M, Ramachandran C, Bermejo Sanz M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85–96.
2. Cook JA, Davit B, Polli JE. Impact of biopharmaceutics classification system-based biowaivers. Mol Pharm. 2010;7(5):1539–44.
3. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
4. CDER/FDA FDA Guidance for Industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Rockville, MD, USA; 2015.
5. EMA. EMA/CHMP: guidelines on the investigation of Bioequivalence. London; 2010.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献